1-O-methyl (3R)-3-hydroxysuccinate | 109361-88-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 1-O-methyl (3R)-3-hydroxysuccinate
• 英文别名: (R)-malic acid；(R)-3-(methoxycarbonyl)-2-hydroxypropanoic acid；Malic acid 4-Me ester；(2R)-2-hydroxy-4-methoxy-4-oxobutanoic acid
• CAS: 109361-88-8
• 化学式: C₅H₈O₅
• 分子量: 148.116
• InChiKey: ZJDXMXMEZZVUKO-GSVOUGTGSA-N

物化性质

• 沸点：
  357.7±27.0 °C(Predicted)
• 密度：
  1.383±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-O-methyl (3R)-3-hydroxysuccinate 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 silver(l) oxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 65.0h， 生成 (2R)-4-methoxy-4-oxo-2-propan-2-yloxybutanoic acid
  参考文献：
  名称：

  Matrix Metalloproteinase Inhibitors:  A Structure−Activity Study

  摘要：

  Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.

  DOI：

  10.1021/jm970494j
• 作为产物：
  描述：

  methyl 2-((R)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetate 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 1-O-methyl (3R)-3-hydroxysuccinate
  参考文献：
  名称：

  [EN] QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS
  [FR] QUINAZOLINES UTILES EN TANT QUE MODULATEURS DE CANAUX IONIQUES

  摘要：

  本发明涉及作为电压门控钠通道抑制剂的化合物。该发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。

  公开号：

  WO2006028904A1

文献信息

• Exploring the potential of the β-thiolactones in bioorganic chemistry
  作者：Sylvain Aubry、Kaname Sasaki、Laure Eloy、Geneviève Aubert、Pascal Retailleau、Thierry Cresteil、David Crich

  DOI：10.1039/c1ob05967j

  日期：——

  A series of novel peptide-based β-thiolactones were synthesized and assayed for cytotoxicity against several human cancer cell lines, where they showed greater activity than the corresponding β-lactones and β-lactams. Several of the β-thiolactones prepared showed strong inhibitory activity in vitro against human cathepsins B and L.

  一系列新型肽基β-硫内酯被合成并测试了其对多个人类癌细胞系的细胞毒性，结果表明它们比相应的β-内酯和β-内酰胺更具活性。所制备的几种β-硫内酯在体外表现出对人类组织蛋白酶B和L的强烈抑制活性。
• Total Synthesis of (−)-Marinisporolide C
  作者：Luiz C. Dias、Emilio C. de Lucca

  DOI：10.1021/acs.joc.7b00023

  日期：2017.3.17

  The first total synthesis of (−)-marinisporolide C is described, which establishes unequivocally the relative and absolute configuration of this oxopolyene macrolide. Key features of this synthesis include a series of highly stereoselective aldol reactions followed by directed reductions to build the polyol domain, a Stille cross-coupling reaction to assemble the polyene, and an intramolecular Hor

  描述了（-）-马尼泊内酯C的第一个全合成，明确地确定了该氧代多烯大环内酯的相对和绝对构型。该合成的关键特征包括一系列高度立体选择性的羟醛反应，然后进行直接还原以构建多元醇结构域，进行斯蒂勒交叉偶联反应以组装多烯，以及分子内的霍纳-沃兹沃思-埃蒙斯烯化反应形成大环。尽管最初的方法是使用Yamaguchi大内酯化反应来制备马来酸A，但由于C33位置的氧存在空间位阻而未能成功，但我们仍能够制备已知的马来酸A的衍生物，从而证实其立体化学结构。
• Quinazolines useful as modulators of ion channels
  申请人：Wilson Dean

  公开号：US20060173018A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及作为电压门控钠通道抑制剂有用的化合物。本发明还提供了包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。